Peresolimab showed efficacy in a phase 2a trial in patients with rheumatoid arthritis. These results provide evidence that stimulation of the PD-1 receptor has potential efficacy in the treatment of rheumatoid arthritis. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT04634253.).
No takes yet. Share an insight, caveat, or question.
Tuttle et al. (2023) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: